| Literature DB >> 470088 |
A U Buzdar, G R Blumenschein, J U Gutterman, C K Tashima, G N Hortobagyi, T L Smith, L T Campos, W L Wheeler, E M Hersh, E J Freireich, E A Gehan.
Abstract
Two hundred twenty-two patients with stage II or III breast cancer following regional therapy were treated with a combination of fluorouracil, doxorubicin hydrochloride (Adrimycin), cyclophosphamide, and BCG vaccine. At 54 months of study (median follow-up, 30 months), the estimated proportions remaining disease-free two and three years after surgery were 83%and 78%, respectively, in the chemotherapy group and 64% and 55%, respectively, in 151 historical control patients. Estimated two- and three-year survival rates were 93% and 89%, respectively, in the chemotherapy group and 84% and 58%, respectively, in the control patients. Congestive heart failure has developed in three patients, possibly related to the use of doxorubicin. Adjuvant chemotherapy with these drugs was effective in prolonging the disease-free interval and survival of patients irrespective of menopausal status, degree of nodal involvement, or stage of the disease.Entities:
Mesh：
Substances：
Year: 1979 PMID： 470088
Source DB: PubMed Journal: JAMA ISSN： 0098-7484 Impact factor: 56.272